صفحه 1 از جانب 41 نتایج
The present invention relates to heparin-based compositions as well as to a process for their preparation and to their therapeutic applications.
The invention relates more particularly to heparin-based compositions neutralized with protamine, having antithrombotic activity but largely devoid of
FIELD OF INVENTION
The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject at risk for or suffering from shock, hemorrhagic shock (HS) or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth
FIELD OF INVENTION
The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject at risk for or suffering from shock, hemorrhagic shock (HS) or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth
BACKGROUND OF THE INVENTION
Field of the Invention
This invention generally relates to a coating having heparin attached thereto on an implantable device, such as a stent.
Description of the Background
Blood has a property of being coagulated by the action of various components in blood when it has
BACKGROUND OF THE INVENTION
The present invention relates to vascular prostheses, and more particularly relates to vascular grafts impregnated with a heparin-containing collagen sealant.
Vascular prostheses, commonly referred to as grafts, are typically used as soft tissue prostheses to replace
The present invention refers to purified heparins, purified heparin fractions and fragments, processes for the preparation thereof and pharmaceutical compositions containing them.
Heparin is a biopolymer extracted from tissues of different kind: bovine or porcine, intestinal mucosa, lung etc.
The
BACKGROUND OF THE INVENTION
The present invention relates to vascular prostheses, and more particularly relates to vascular grafts impregnated with a heparin-containing collagen sealant.
Vascular prostheses, commonly referred to as grafts, are typically used as soft tissue prostheses to replace
BACKGROUND OF THE INVENTION
1. Field Of The Invention
This invention relates to the use of t-PA and a heparin fraction which has low affinity for t-PA in a composition for thrombolytic therapy.
2. Background Of The Related Art
Pathologies of blood coagulation such as heart attacks, strokes, and the
TECHNICAL FIELD
The present application relates to combinations of a heparin cofactor II agonist and a platelet glycoprotein IIb/IIIa receptor (GPIIb/IIIa) antagonist that are useful in inhibiting both platelet aggregation and thrombin generation resulting from disease, or injury responses to wound
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention generally relates to a prodrug formed of heparin and a drug and drug-delivery stents formed from a material having the prodrug.
2. Description of the Background
Blood has a property of being coagulated by the action of various
FIELD OF THE INVENTION
This invention generally relates to a prodrug formed of heparin and a drug and drug-delivery stents formed from a material having the prodrug.
DESCRIPTION OF THE BACKGROUND
Blood has a property of being coagulated by the action of various components in blood when it has come
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention generally relates to a prodrug formed of heparin and a drug and drug-delivery stents formed from a material having the prodrug.
2. Description of the Background
Blood has a property of being coagulated by the action of various
FIELD OF THE INVENTION
This invention generally relates to a prodrug formed of heparin and a drug and drug-delivery stents formed from a material having the prodrug.
DESCRIPTION OF THE BACKGROUND
Blood has a property of being coagulated by the action of various components in blood when it has come
BACKGROUND OF THE INVENTION
The invention pertains to medical methods, compounds and devices and, particularly, to the treatment of abnormal uterine bleeding and to improved female contraception.
A common cause of abnormal uterine bleeding is the presence of leiomyomas, or fibroids, in the uterus.
This invention relates to a physico-chemical process for manufacturing oligosaccharide fractions from commercial heparin having useful pharmaceutical properties, such as: high inhibition of the Xa factor, high antithrombotic, and low anticoagulant activity.
Heparin is a polydisperse polymer of the